Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis In Pancreatic Cancer Cells And Enhances Gemcitabine Efficacy, Advait Shetty, Prashanth K.B. Nagesh, Saini Setua, Bilal B. Hafeez, Meena Jaggi, Murali M. Yallapu, Subhash C. Chauhan
Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis In Pancreatic Cancer Cells And Enhances Gemcitabine Efficacy, Advait Shetty, Prashanth K.B. Nagesh, Saini Setua, Bilal B. Hafeez, Meena Jaggi, Murali M. Yallapu, Subhash C. Chauhan
School of Medicine Publications and Presentations
Pancreatic cancer (PanCa) is a highly lethal disease with a poor 5 year survival rate, less than 7%. It has a dismal prognosis, and more than 50% of cases are detected at an advanced and metastatic stage. Gemcitabine (GEM) is a gold standard chemotherapy used for PanCa treatment. However, GEM-acquired resistance in cancer cells is considered as a major setback for its continued clinical implementation. This phenomenon is evidently linked to de novo lipid synthesis. PanCa cells rely on de novo lipid synthesis, which is a prime event in survival and one of the key drivers for tumorigenesis, cancer progression, …